Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Chief Tech. Off. & Site Head | February 22, 2018 | February 26, 2018 |
| Pulmatrix, Inc.PULM · Entity 8249 | Director | January 26, 2023 | January 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date February 22, 2018 · Filed February 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,513 |
Reported balance
After 2018-02-22 transaction · row 1
1 source rowRow 1 · 2018-02-22 · Grant · Acquired 5,197 · Balance 55,513 F1: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded.
Pulmatrix, Inc.
Report date January 26, 2023 · Filed January 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2033-01-26 | Direct | 1,700 |
Reported balance
After 2023-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-26 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2023 Filed Jan 30, 2023 21:05 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001493152-23-002913 · ownership.xml · derivative · entry 1 Batycky Richard P. · CIK 0001646596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2033-01-26 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 14:38 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 22,100 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001493152-22-002678 · ownership.xml · derivative · entry 1 Batycky Richard P. · CIK 0001646596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2032-01-27 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 02:45 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001493152-21-002322 · ownership.xml · derivative · entry 1 Batycky Richard P. · CIK 0001646596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 13:17 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000899243-20-010273 · doc4.xml · derivative · entry 1 Batycky Richard P. · CIK 0001646596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-04-02 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 2, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:17 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000899243-20-001092 · doc4.xml · derivative · entry 1 Batycky Richard P. · CIK 0001646596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: Twenty-five percent (25%) of this option will vest and become exercisable on November 1, 2020 (the "First Vesting Date"), and the remaining shares underlying the option will vest and become exercisable in thirty-six (36) equal monthly installments on each monthly anniversary of the First Vesting Date thereafter, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 08:25 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013207 · doc4.xml · nonDerivative · entry 1 Batycky Richard P. · CIK 0001646596 · Chief Tech. Off. & Site Head 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,513 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-17-029649 · doc4.xml · derivative · entry 1 Batycky Richard P. · CIK 0001646596 · Chief Tech. Off. & Site Head 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-05-01 F1 · derivative.exercise_date: The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% to vest at the end of six months after the grant date and the remaining 75% to vest in equal quarterly installments over the remainder of such two year period. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:02 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $27.48 | $0.00 |
DisclosureSEC source: 0001209191-17-017388 · doc4.xml · derivative · entry 2 Batycky Richard P. · CIK 0001646596 · Chief Tech. Off. & Site Head 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-01 F2 · derivative.exercise_date: The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:02 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-017388 · doc4.xml · nonDerivative · entry 1 Batycky Richard P. · CIK 0001646596 · Chief Tech. Off. & Site Head 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,316 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 07:06 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 2,063 | $20.30 | $41,877.25 |
DisclosureSEC source: 0001209191-16-146806 · doc4.xml · nonDerivative · entry 1 Batycky Richard P. · CIK 0001646596 · Chief Tech. Off. & Site Head 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,916 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.10 to $20.50 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.